Evidence map›Paper›PMID 35625741›Full record

ArticleBiomedicines2022

Whole-Exome Sequencing of Germline Variants in Non-

Yaxuan Liu, Hafdis T Helgadottir, Pedram Kharaziha, Jungmin Choi, Francesc López-Giráldez, Shrikant M Mane, Veronica Höiom, Carl Christofer Juhlin, Catharina Larsson, Svetlana Bajalica-Lagercrantz

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Yaxuan LiuDepartment of Oncology-Pathology, Karolinska Institutet, Bioclinicum, Karolinska University Hospital, 17176 Stockholm, Sweden.ORCID 0000-0001-5848-419X
Hafdis T HelgadottirDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 17176 Stockholm, Sweden.
Pedram KharazihaDepartment of Oncology-Pathology, Karolinska Institutet, Bioclinicum, Karolinska University Hospital, 17176 Stockholm, Sweden.
Jungmin ChoiYale Center for Genome Analysis, Yale University, New Haven, CT 06511, USA.
Francesc López-GiráldezYale Center for Genome Analysis, Yale University, New Haven, CT 06511, USA.
Shrikant M ManeYale Center for Genome Analysis, Yale University, New Haven, CT 06511, USA.
Veronica HöiomDepartment of Oncology-Pathology, Karolinska Institutet, Bioclinicum, Karolinska University Hospital, 17176 Stockholm, Sweden.
Carl Christofer JuhlinDepartment of Oncology-Pathology, Karolinska Institutet, Bioclinicum, Karolinska University Hospital, 17176 Stockholm, Sweden.ORCID 0000-0002-5945-9081
Catharina LarssonDepartment of Oncology-Pathology, Karolinska Institutet, Bioclinicum, Karolinska University Hospital, 17176 Stockholm, Sweden.
Svetlana Bajalica-LagercrantzDepartment of Oncology-Pathology, Karolinska Institutet, Bioclinicum, Karolinska University Hospital, 17176 Stockholm, Sweden.ORCID 0000-0002-7175-7102
Karolinska University Hospital · SEYale University · USKorea University · KR

Funding

Cancer Bioinformatics: Data analysis and method development for the Yale Cancer CenterR50CA265359 · NCI · YALE UNIVERSITY · PI Juan Francisco Lopez Giraldez · 2022 to 2026
$699k
CSRD VA 1NCI NIH HHS R50 CA265359
6 · The paper itself

Abstract

Breast cancer is the most prevalent malignancy among women worldwide and hereditary breast cancer (HBC) accounts for about 5−10% of the cases. Today, the most recurrent genes known are BRCA1 and BRCA2, accounting for around 25% of familial cases. Although thousands of loss-of-function variants in more than twenty predisposing genes have been found, the majority of familial cases of HBC remain unexplained. The aim of this study was to identify new predisposing genes for HBC in three non-BRCA families with autosomal dominant inheritance pattern using whole-exome sequencing and functional prediction tools. No pathogenic variants in known hereditary cancer-related genes could explain the breast cancer susceptibility in these families. Among 2122 exonic variants with maximum minor allele frequency (MMAF) < 0.1%, between 17−35 variants with combined annotation-dependent depletion (CADD) > 20 segregated with disease in the three analyzed families. Selected candidate genes, i.e., UBASH3A, MYH13, UTP11L, and PAX7, were further evaluated using protein expression analysis but no alterations of cancer-related pathways were observed. In conclusion, identification of new high-risk cancer genes using whole-exome sequencing has been more challenging than initially anticipated, in spite of selected families with pronounced family history of breast cancer. A combination of low- and intermediate-genetic-risk variants may instead contribute the breast cancer susceptibility in these families.

Indexed as

bioinformaticsgermline variantshereditary breast cancerwhole-exome sequencing

Identifiers

PMID35625741
PMCPMC9138793
OpenAlexW4224942330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.